Artículos

Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study https://www.ejcancer.com/article/S0959-8049(26)00556-3/fulltext

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01850-1/fulltext?dgcid=raven_jbs_etoc_feature_lancet

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neckhttps://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1226939/full